Canopy Growth Nears Acquisition Finish Line Amid Cautious Market Sentiment

Canopy Growth nears MTL Cannabis acquisition with shareholder approval, but faces a 'Reduce' rating from analysts despite improved financials and a path to 2027 profitability.

Canopy Growth Corporation finds itself at a critical juncture. The company is advancing toward the completion of its strategic acquisition of MTL Cannabis, a move designed to bolster its standing in Canada's medical cannabis sector. However, this operational progress is being weighed against a backdrop of persistent analyst skepticism and a challenging stock performance.

Shareholder Approval Secured, Court Decision Pending

The path to acquiring MTL Cannabis cleared a major hurdle on February 18, 2026. Shareholders of the target company voted overwhelmingly in favor of the transaction, with 99.97 percent casting ballots to approve the deal. This strong endorsement paves the way for the final step: approval from the Supreme Court of British Columbia. A hearing is scheduled for February 23, 2026.

Management at Canopy Growth anticipates closing the transaction before the end of March 2026. The deal, involving a cash payment of between 40 and 50 million CAD, is characterized by CEO Luc Mongeau as a strategically essential step to secure a leadership position within the Canadian medical cannabis market. The company expects the acquisition to be accretive to value.

Financial Improvements Contrast with Analyst "Reduce" Stance

Despite this forward momentum on the M&A front, the market's reception remains tepid. The prevailing analyst consensus as of February 18, 2026, is a "Reduce" rating. Recent downgrades have been issued by firms including Weiss Ratings and Wall Street Zen. Canopy Growth's shares are currently trading in a range around $1.09 to $1.17 USD, a level significantly below their 52-week highs.

Investors are balancing the acquisition news against the firm's latest financial results. For the third fiscal quarter, which concluded on December 31, 2025, Canopy Growth reported a net loss that was 49 percent lower year-over-year. Its adjusted EBITDA showed a loss of just 3 million CAD, marking a 17 percent improvement. The company also holds a cash position of 371 million CAD. Nevertheless, profitability remains elusive, with leadership targeting a return to the black by fiscal year 2027.

The Road Ahead: Integration and the Path to Profitability

The immediate focus is the court's decision on February 23, which will determine the precise timeline for finalizing the takeover. A favorable ruling would allow Canopy Growth to proceed with integrating MTL Cannabis, a process expected to meaningfully strengthen its medical division.

The broader challenge, however, extends beyond this single transaction. While cost structure improvements are evident, the journey to the company's stated goal of profitability in 2027 is a multi-year endeavor. The coming weeks will reveal not only the fate of the acquisition but also whether operational gains can begin to shift the cautious narrative surrounding the stock.